NL139166B - Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking. - Google Patents

Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking.

Info

Publication number
NL139166B
NL139166B NL696914077A NL6914077A NL139166B NL 139166 B NL139166 B NL 139166B NL 696914077 A NL696914077 A NL 696914077A NL 6914077 A NL6914077 A NL 6914077A NL 139166 B NL139166 B NL 139166B
Authority
NL
Netherlands
Prior art keywords
preparing
medicinal product
blocking action
beta adrenergic
adrenergic blocking
Prior art date
Application number
NL696914077A
Other languages
English (en)
Other versions
NL6914077A (nl
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NL6914077A publication Critical patent/NL6914077A/xx
Publication of NL139166B publication Critical patent/NL139166B/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/38—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
NL696914077A 1968-09-23 1969-09-17 Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking. NL139166B (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76185768A 1968-09-23 1968-09-23

Publications (2)

Publication Number Publication Date
NL6914077A NL6914077A (nl) 1970-03-25
NL139166B true NL139166B (nl) 1973-06-15

Family

ID=25063434

Family Applications (1)

Application Number Title Priority Date Filing Date
NL696914077A NL139166B (nl) 1968-09-23 1969-09-17 Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking.

Country Status (15)

Country Link
US (1) US3641152A (nl)
JP (1) JPS4843734B1 (nl)
BE (1) BE739195A (nl)
CH (1) CH525183A (nl)
DE (2) DE1967162C3 (nl)
DK (2) DK125588B (nl)
ES (1) ES371737A1 (nl)
FI (1) FI51936C (nl)
FR (1) FR2018626B1 (nl)
GB (1) GB1223527A (nl)
IT (1) IT1033032B (nl)
NL (1) NL139166B (nl)
NO (1) NO128869B (nl)
SE (1) SE362414B (nl)
ZA (1) ZA695648B (nl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755071A (fr) * 1969-09-17 1971-02-22 Warner Lambert Pharmaceutical Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone
US3959486A (en) * 1970-05-27 1976-05-25 Imperial Chemical Industries Limited Method for producing β-adrenergic blockage with alkanolamine derivatives
DE2130393C3 (de) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2119843B1 (nl) * 1970-12-28 1974-03-22 Laroche Navarro Labo
JPS5122737Y2 (nl) * 1972-12-30 1976-06-11
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
GB1493848A (en) * 1975-07-24 1977-11-30 Beecham Group Ltd Aryltetralins
CH621330A5 (nl) * 1976-05-14 1981-01-30 Sandoz Ag
DE2810869A1 (de) * 1977-03-24 1978-09-28 Sandoz Ag 3-amino-2-hydroxypropoxy-derivate, ihre herstellung und verwendung
US4176183A (en) * 1977-05-02 1979-11-27 Merck & Co., Inc. Novel naphthyridines
US4270005A (en) * 1977-11-14 1981-05-26 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
CH641147A5 (de) * 1979-01-17 1984-02-15 Sandoz Ag 3-amino-2-hydroxypropoxyaryl-derivat, seine herstellung und dieses enthaltende heilmittel.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
FR2507181A1 (fr) * 1981-06-05 1982-12-10 Sanofi Sa Nouveaux ethers de phenol actifs sur le systeme cardiovasculaire, leur procede de preparation et leur utilisation dans des medicaments
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
ES2065278B1 (es) * 1993-06-24 1995-09-01 Medichem Sa Procedimiento de obtencion enantioselectivo del levobunolol.
ATE330633T1 (de) * 2000-07-27 2006-07-15 Pharmacia Corp Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1023214A (en) * 1962-12-17 1966-03-23 Ici Ltd Carbocyclic hydroxyamines

Also Published As

Publication number Publication date
DE1948144B2 (de) 1979-05-03
FI51936B (nl) 1977-01-31
FI51936C (fi) 1977-05-10
ES371737A1 (es) 1972-03-16
US3641152A (en) 1972-02-08
ZA695648B (en) 1971-03-31
DK125588B (da) 1973-03-12
NL6914077A (nl) 1970-03-25
BE739195A (nl) 1970-03-23
GB1223527A (en) 1971-02-24
IT1033032B (it) 1979-07-10
NO128869B (nl) 1974-01-21
CH525183A (de) 1972-07-15
FR2018626B1 (nl) 1973-06-08
DE1967162C3 (de) 1981-03-19
SE362414B (nl) 1973-12-10
FR2018626A1 (nl) 1970-06-26
DE1948144A1 (de) 1970-03-26
JPS4843734B1 (nl) 1973-12-20
DE1967162B1 (de) 1980-07-31
DE1948144C3 (de) 1980-01-17
DK128536B (da) 1974-05-20

Similar Documents

Publication Publication Date Title
NL151374B (nl) Werkwijze voor het bereiden van een geneesmiddel met een prolactineremmende werking alsmede van een hierbij bruikbaar alfa-ergokryptinederivaat.
NL146378B (nl) Werkwijze voor het bereiden van een geneesmiddel met diuretische werking.
NL7809942A (nl) Werkwijze voor het bereiden van een geneesmiddel met blokkerende werking op beta-adrenergische receptoren onder toepassing van een fenylaminoethanolderivaat.
NL158176B (nl) Werkwijze voor het bereiden van een geneesmiddel met (beta)-adrenenergisch blokkerende werking, gevormd geneesmiddel verkregen onder toepassing daarvan, alsmede werkwijze voor het bereiden van een verbinding geschikt voor toepassing bij voornoemde werkwijze.
NL139166B (nl) Werkwijze voor het bereiden van een geneesmiddel met beta-adrenergisch blokkerende werking.
NL142590B (nl) Werkwijze voor het bereiden van een geneesmiddel met anti-bacteriele werking.
NL140237B (nl) Werkwijze voor het bereiden van een geneesmiddel met kalmerende werking.
NL174550C (nl) Werkwijze ter bereiding van een lactatieremmende verbinding, werkwijze voor het bereiden van een geneesmiddel met lactatieremmende werking en gevormd geneesmiddel.
NL170734C (nl) Werkwijze voor het bereiden van een geneesmiddel met antibacteriele werking en werkwijze voor het bereiden van daarbij te gebruiken geneeskrachtige verbindingen.
NL163788C (nl) Werkwijze ter bereiding van een geneesmiddel met neuro- trope en psychotrope werking, alsmede werkwijze voor het bereiden van een geneeskrachtig dibenzothiepien of dibenzooxepienderivaat.
NL142672B (nl) Werkwijze voor het bereiden van een geneesmiddel met een cholesterolspiegelverlagende werking, en werkwijze voor het bereiden van geneeskrachtige verbindingen daarvoor.
NL143924B (nl) Werkwijze voor het bereiden van een geneesmiddel tegen hypertensie.
NL172653C (nl) Werkwijze voor het bereiden van een geneesmiddel met antimycotische werking en werkwijze voor het bereiden van geneeskrachtige joodpropargyloxyareenderivaten.
NL154116B (nl) Werkwijze voor het bereiden van een geneesmiddel met anti-bacteriele werking, alsmede het gevormde geneesmiddel.
NL141188B (nl) Werkwijze voor het bereiden van een geneesmiddel.
NL138934B (nl) Werkwijze voor het bereiden van een geneesmiddel met anti-inflammatoire werking.
NL175721C (nl) Werkwijze voor het bereiden of vervaardigen van een geneesmiddel met anticholinergische werking.
NL142687B (nl) Werkwijze ter bereiding van een farmaceutisch of veterinair geneesmiddel met anthelmintische werking.
NL144613B (nl) Werkwijze voor het bereiden van een derivaat van d-6-methylergoleen met bloeddrukverlagende werking.
NL175254C (nl) Werkwijze voor het bereiden van een preparaat met fungicide werking.
NL175825C (nl) Werkwijze voor het bereiden of vervaardigen van een geneesmiddel met antilipidemische werking.
NL160255C (nl) Werkwijze voor het bereiden van een geneesmiddel met anti-depressieve werking.
NL144608B (nl) Werkwijze voor het bereiden van een geneesmiddel met anti-inflammatoire werking.
NL160331C (nl) Werkwijze voor het bereiden van een preparaat met reini- gende werking.
NL142401B (nl) Werkwijze voor het bereiden van een geneesmiddel met bloedlipidenspiegel-verlagende werking.

Legal Events

Date Code Title Description
NL80 Abbreviated name of patent owner mentioned of already nullified patent

Owner name: WARNER LAMBERT

V4 Discontinued because of reaching the maximum lifetime of a patent